Amine A Kamen

List of Publications by Year
in descending order

145 papers	7,067 citations	46918 47 h-index	71532 76 g-index
147 all docs	147 docs citations	147 times ranked	6183 citing authors

#	Article	IF	Citations
1	High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Research, 2002, 30, 9e-9.	6.5	913
2	Effect of Surface Charge on the Cellular Uptake and Cytotoxicity of Fluorescent Labeled Cellulose Nanocrystals. ACS Applied Materials & Interfaces, 2010, 2, 2924-2932.	4.0	286
3	Large-Scale Transfection of Mammalian Cells for the Fast Production of Recombinant Protein. Molecular Biotechnology, 2006, 34, 225-238.	1.3	203
4	Development and optimization of an adenovirus production process. Journal of Gene Medicine, 2004, 6, S184-S192.	1.4	168
5	Production of adenovirus vector for gene therapy. Biotechnology Advances, 2003, 20, 475-489.	6.0	135
6	Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnology and Bioengineering, 1998, 59, 567-575.	1.7	130
7	Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: Peptone additives improve cell growth and transfection efficiency. Biotechnology and Bioengineering, 2003, 84, 332-342.	1.7	125
8	A Reporter Gene Assay for High-Throughput Screening of G-Protein-Coupled Receptors Stably or Transiently Expressed in HEK293 EBNA Cells Grown in Suspension Culture. Analytical Biochemistry, 2000, 284, 316-326.	1.1	118
9	Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology, 1994, 15, 145-155.	0.7	117
10	Development of a scalable process for highâ€yield lentiviral vector production by transient transfection of HEK293 suspension cultures. Journal of Gene Medicine, 2009, 11, 868-876.	1.4	117
11	Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines. BioMed Research International, 2015, 2015, 1-11.	0.9	116
12	On-line monitoring of respiration in recombinant-baculovirus infected and uninfected insect cell bioreactor cultures. , 1996, 50, 36-48.		114
13	Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnology and Bioengineering, 2007, 98, 789-799.	1.7	113
14	Growth, nutrient consumption, and end-product accumulation in Sf-9 and BTI-EAA insect cell cultures: Insights into growth limitation and metabolism. Biotechnology Progress, 1993, 9, 615-624.	1.3	111
15	Monitoring Motility, Spreading, and Mortality of Adherent Insect Cells Using an Impedance Sensor. Analytical Chemistry, 2001, 73, 1844-1848.	3.2	111
16	Adenovirus-Mediated Utrophin Gene Transfer Mitigates the Dystrophic Phenotype of mdx Mouse Muscles. Human Gene Therapy, 1999, 10, 1299-1310.	1.4	108
17	Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Review of Vaccines, 2011, 10, 1063-1081.	2.0	106
18	Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine, 2010, 28, 3661-3671.	1.7	87

#	Article	IF	Citations
19	Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnology Advances, 2006, 24, 321-337.	6.0	83
20	Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells. Journal of Biotechnology, 2007, 128, 268-280.	1.9	82
21	A TrkA-selective, Fast Internalizing Nerve Growth Factor-Antibody Complex Induces Trophic but Not Neuritogenic Signals. Journal of Biological Chemistry, 1998, 273, 34933-34940.	1.6	78
22	A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnology and Bioengineering, 2005, 90, 391-404.	1.7	77
23	Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. Journal of Virological Methods, 2007, 144, 32-40.	1.0	77
24	Enhanced growth of sf-9 cells to a maximum density of 5.2 Ã— 107 cells per mL and production of Î²-galactosidase at high cell density by fed batch culture. , 2000, 68, 381-388.		76
25	Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures. Biotechnology and Bioengineering, 2004, 86, 765-774.	1.7	76
26	Probing inhibitory effects of nanocrystalline cellulose: inhibition versus surface charge. Nanoscale, 2012, 4, 1373.	2.8	76
27	Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. Journal of Virological Methods, 2014, 196, 163-173.	1.0	75
28	Quantitation of baculovirus particles by flow cytometry. Journal of Virological Methods, 2002, 105, 321-330.	1.0	73
29	Size-Exclusion Chromatography Purification of High-Titer Vesicular Stomatitis Virus G Glycoprotein-Pseudotyped Retrovectors for Cell and Gene Therapy Applications. Human Gene Therapy, 2003, 14, 1139-1153.	1.4	69
30	Production of Recombinant Adeno-Associated Viral Vectors Using a Baculovirus/Insect Cell Suspension Culture System: From Shake Flasks to a 20-L Bioreactor. Biotechnology Progress, 2008, 21, 154-160.	1.3	66
31	Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnology Advances, 2020, 44, 107608.	6.0	66
32	Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnology Advances, 2008, 26, 73-88.	6.0	63
33	Manufacturing of recombinant adenoâ€associated viruses using mammalian expression platforms. Biotechnology Journal, 2017, 12, 1600193.	1.8	62
34	Improving Glucose and Glutamine Metabolism of Human HEK 293 and Trichoplusia ni Insect Cells Engineered To Express a Cytosolic Pyruvate Carboxylase Enzyme. Biotechnology Progress, 2003, 19, 90-97.	1.3	61
35	Stability of Serum-Free and Purified Baculovirus Stocks under Various Storage Conditions. Biotechnology Progress, 2006, 22, 319-325.	1.3	61
36	Identification of Host Proteins Associated with Retroviral Vector Particles by Proteomic Analysis of Highly Purified Vector Preparations. Journal of Virology, 2008, 82, 1107-1117.	1.5	61

#	Article	IF	Citations
37	Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virology Journal, 2013, 10, 141.	1.4	61
38	Metabolic and Kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnology, 2011, 11, 84.	1.7	60
39	Acoustic cell filter: a proven cell retention technology for perfusion of animal cell cultures. Biotechnology Advances, 2004, 22, 433-444.	6.0	59
40	Understanding factors that limit the productivity of suspension-based perfusion cultures operated at high medium renewal rates. , 2000, 67, 435-450.		58
41	Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnology, 2015, 15, 31.	1.7	57
42	Dystrophin Expression in Muscle Following Gene Transfer with a Fully Deleted ("Gutted") Adenovirus Is Markedly Improved by Trans-Acting Adenoviral Gene Products. Human Gene Therapy, 2001, 12, 1741-1755.	1.4	56
43	On-Line Monitoring of Physiological Parameters of Insect Cell Cultures during the Growth and Infection Process. Biotechnology Progress, 2000, 16, 803-808.	1.3	55
44	Use of the Centritech Lab Centrifuge for Perfusion Culture of Hybridoma Cells in Protein-Free Medium. Biotechnology Progress, 1996, 12, 855-864.	1.3	54
45	Advancements in mammalian cell transient gene expression (TGE) technology for accelerated production of biologics. Critical Reviews in Biotechnology, 2018, 38, 918-940.	5.1	54
46	Overview of Current Scalable Methods for Purification of Viral Vectors. Methods in Molecular Biology, 2011, 737, 89-116.	0.4	53
47	Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-Pseudotyped Retroviral Vectors Produced in Suspension and Serum-Free Media. Human Gene Therapy, 2009, 20, 966-974.	1.4	52
48	Study of Adenovirus Production in Serum-Free 293SF Suspension Culture by GFP-Expression Monitoring. Biotechnology Progress, 1997, 13, 709-714.	1.3	51
49	Adaptive Control at Low Glucose Concentration of HEK-293 Cell Serum-Free Cultures. Biotechnology Progress, 1999, 15, 608-616.	1.3	50
50	High yield purification of functional baculovirus vectors by size exclusion chromatography. Journal of Virological Methods, 2007, 142, 21-28.	1.0	50
51	Baculovirus expression system scaleup by perfusion of high-density Sf-9 cell cultures. Biotechnology and Bioengineering, 1994, 43, 881-891.	1.7	48
52	Production of adeno-associated viral vectors in insect cells using triple infection: Optimization of baculovirus concentration ratios. Biotechnology and Bioengineering, 2006, 95, 1081-1092.	1.7	47
53	Purification of recombinant proteins from mammalian cell culture using a generic double-affinity chromatography scheme. Protein Expression and Purification, 2005, 40, 77-85.	0.6	46
54	Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. Journal of Virological Methods, 2007, 139, 61-70.	1.0	46

#	Article	IF	Citations
55	Advancements in the design and scalable production of viral gene transfer vectors. Biotechnology and Bioengineering, 2018, 115, 25-40.	1.7	45
56	Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. Vaccine, 2016, 34, 3371-3380.	1.7	44
57	Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. Biomedical Applications, 2001, 755, 27-36.	1.7	43
58	Development of suspension adapted Vero cell culture process technology for production of viral vaccines. Vaccine, 2019, 37, 6996-7002.	1.7	42
59	Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. Journal of Virological Methods, 2006, 133, 82-91.	1.0	41
60	Probing Inhibitory Effects of Antrodia camphorata Isolates Using Insect Cell-Based Impedance Spectroscopy: Inhibition vs Chemical Structure. Chemical Research in Toxicology, 2008, 21, 2127-2133.	1.7	39
61	Largeâ€scale adenovirus and poxvirusâ€vectored vaccine manufacturing to enable clinical trials. Biotechnology Journal, 2015, 10, 741-747.	1.8	39
62	Rational plasmid design and bioprocess optimization to enhance recombinant adenoâ€associated virus (AAV) productivity in mammalian cells. Biotechnology Journal, 2016, 11, 290-297.	1.8	38
63	Achieving High-Yield Production of Functional AAV5 Gene Delivery Vectors via Fedbatch in an Insect Cell-One Baculovirus System. Molecular Therapy - Methods and Clinical Development, 2019, 13, 279-289.	1.8	38
64	Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9. Molecular Therapy - Methods and Clinical Development, 2021, 21, 341-356.	1.8	38
65	Improving adenoâ€associated vector yield in high density insect cell cultures. Journal of Gene Medicine, 2010, 12, 157-167.	1.4	36
66	Unraveling the metabolism of HEK-293 cells using lactate isotopomer analysis. Bioprocess and Biosystems Engineering, 2011, 34, 263-273.	1.7	35
67	Influence of HEK293 metabolism on the production of viral vectors and vaccine. Vaccine, 2015, 33, 5974-5981.	1.7	33
68	Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation. Vaccines, 2020, 8, 654.	2.1	32
69	Recent progress in lentiviral vector mass production. Biochemical Engineering Journal, 2010, 48, 362-377.	1.8	31
70	Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor. Biotechnology and Bioengineering, 2006, 95, 653-660.	1.7	30
71	Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). Vaccine, 2012, 30, 300-306.	1.7	30
72	Analysis of baculovirus aggregates using flow cytometry. Journal of Virological Methods, 2006, 134, 8-14.	1.0	29

#	Article	IF	Citations
73	Insights into the Central Metabolism of Spodoptera frugiperda (Sf-9) and Trichoplusia ni BTI-Tn-5B1-4(Tn-5) Insect Cells by Radiolabeling Studies. Biotechnology Progress, 2008, 21, 78-86.	1.3	29
74	Manufacturing of viral vectors for gene therapy: part I. Upstream processing. Pharmaceutical Bioprocessing, 2014, 2, 183-203.	0.8	29
75	Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals. Analyst, The, 2021, 146, 4905-4917.	1.7	28
76	Improving AAV vector yield in insect cells by modulating the temperature after infection. Biotechnology and Bioengineering, 2007, 97, 1501-1509.	1.7	27
77	Validation of a high-performance liquid chromatographic assay for the quantification of adenovirus type 5 particles. Biomedical Applications, 2001, 761, 187-194.	1.7	26
78	A novel polyethyleneimine-coated adeno-associated virus-like particle formulation for efficient siRNA delivery in breast cancer therapy: preparation and in vitro analysis. International Journal of Nanomedicine, 2012, 7, 1575.	3.3	26
79	Advancements in molecular design and bioprocessing of recombinant adenoâ€associated virus gene delivery vectors using the insectâ€cell baculovirus expression platform. Biotechnology Journal, 2021, 16, e2000021.	1.8	26
80	Monitoring lentiviral vector production kinetics using online permittivity measurements. Biochemical Engineering Journal, 2011, 54, 16-25.	1.8	25
81	Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line. Vaccine, 2017, 35, 4220-4228.	1.7	25
82	Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells. Vaccine, 2019, 37, 6624-6632.	1.7	25
83	Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-Xâ„¢ hydro fixed-bed. Journal of Biotechnology, 2020, 310, 32-39.	1.9	24
84	An efficient process for the purification of helper-dependent adenoviral vector and removal of helper virus by iodixanol ultracentrifugation. Journal of Virological Methods, 2010, 165, 83-89.	1.0	23
85	Realâ€time monitoring of influenza virus production kinetics in HEK293 cell cultures. Biotechnology Progress, 2013, 29, 275-284.	1.3	23
86	Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF. Vaccine, 2019, 37, 7100-7107.	1.7	22
87	Multivariable Nonlinear Control of Biomass and Metabolite Concentrations in a High-Cell-Density Perfusion Bioreactor. Industrial & Engineering Chemistry Research, 2006, 45, 8985-8997.	1.8	21
88	Exploiting heparin-binding properties of MoMLV-based retroviral vectors for affinity chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 846, 124-131.	1.2	21
89	Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. Vaccine, 2016, 34, 3381-3387.	1.7	21
90	Critical phases of viral production processes monitored by capacitance. Journal of Biotechnology, 2017, 242, 19-29.	1.9	20

#	Article	IF	Citations
91	RNA interference technology to improve the baculovirus-insect cell expression system. Biotechnology Advances, 2018, 36, 443-451.	6.0	20
92	Reassessing culture media and critical metabolites that affect adenovirus production. Biotechnology Progress, 2010, 26, 200-207.	1.3	19
93	Establishment and validation of new complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture. Journal of Virological Methods, 2014, 208, 177-188.	1.0	18
94	Critical review of current and emerging quantification methods for the development of influenza vaccine candidates. Vaccine, 2015, 33, 5913-5919.	1.7	18
95	Particle quantification of influenza viruses by high performance liquid chromatography. Vaccine, 2015, 33, 78-84.	1.7	18
96	High-performance liquid chromatographic total particles quantification of retroviral vectors pseudotyped with vesicular stomatitis virus-G glycoprotein. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 813, 167-173.	1.2	17
97	A pooled genome-wide screening strategy to identify and rank influenza host restriction factors in cell-based vaccine production platforms. Scientific Reports, 2020, 10, 12166.	1.6	17
98	Manufacturing of Adenovirus Vectors: Production and Purification of Helper Dependent Adenovirus. Methods in Molecular Biology, 2011, 737, 139-156.	0.4	16
99	Virus-like Particle and Viral Vector Production Using the Baculovirus Expression Vector System/Insect Cell System. Methods in Molecular Biology, 2007, 388, 281-296.	0.4	16
100	Development of a suspension serum-free helper-dependent adenovirus production system and assessment of co-infection conditions. Journal of Virological Methods, 2008, 148, 106-114.	1.0	15
101	Hyperosmotic pressure on HEK 293 cells during the growth phase, but not the production phase, improves adenovirus production. Journal of Biotechnology, 2012, 157, 228-236.	1.9	15
102	Endothelial IL-33 Expression Is Augmented by Adenoviral Activation of the DNA Damage Machinery. Journal of Immunology, 2017, 198, 3318-3325.	0.4	15
103	Bioreactor production of rVSVâ€based vectors in Vero cell suspension cultures. Biotechnology and Bioengineering, 2021, 118, 2649-2659.	1.7	15
104	Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures. Vaccines, 2021, 9, 1335.	2.1	15
105	Development and validation of a HPLC method for the quantification of baculovirus particles. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 61-68.	1.2	14
106	Extended gene expression for Gag VLP production achieved at bioreactor scale. Journal of Chemical Technology and Biotechnology, 2019, 94, 302-308.	1.6	14
107	Critical Assessment of Purification and Analytical Technologies for Enveloped Viral Vector and Vaccine Processing and Their Current Limitations in Resolving Co-Expressed Extracellular Vesicles. Vaccines, 2021, 9, 823.	2.1	14
108	Haplotype-resolved de novo assembly of the Vero cell line genome. Npj Vaccines, 2021, 6, 106.	2.9	14

#	Article	IF	Citations
109	Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections. Human Gene Therapy, 2018, 29, 452-466.	1.4	13
110	Development of a vectored vaccine against Hepatitis E virus. Vaccine, 2014, 32, 2808-2811.	1.7	12
111	Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics. Vaccine, 2017, 35, 3423-3430.	1.7	12
112	Titration methods for rVSV-based vaccine manufacturing. MethodsX, 2020, 7, 100806.	0.7	12
113	Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	12
114	Probing inhibitory effects of destruxins from Metarhizium anisopliae using insect cell based impedance spectroscopy: inhibition vs chemical structure. Analyst, The, 2009, 134, 1447.	1.7	11
115	Development and Validation of an Anion Exchange High-Performance Liquid Chromatography Method for Analysis of Empty Capsids and Capsids Encapsidating Genetic Material in a Purified Preparation of Recombinant Adeno-Associated Virus Serotype 5. Human Gene Therapy, 2021, 32, 1390-1402.	1.4	11
116	An initiative to manufacture and characterize baculovirus reference material. Journal of Invertebrate Pathology, 2011, 107, S113-S117.	1.5	10
117	Only a small fraction of cells produce assembled capsids during transfectionâ€based manufacturing of adenoâ€associated virus vectors. Biotechnology and Bioengineering, 2022, 119, 1685-1690.	1.7	10
118	Evaluation of homogeneity and genetic stability of REOLYSINÂ® (pelareorep) by complete genome sequencing of reovirus after large scale production. Applied Microbiology and Biotechnology, 2014, 98, 1763-1770.	1.7	9
119	Adenoâ€Associated Viral Vectors for Homologyâ€Directed Generation of CARâ€T Cells. Biotechnology Journal, 2020, 15, e1900286.	1.8	9
120	Rapid In-Process Monitoring of Lentiviral Vector Particles by High-Performance Liquid Chromatography. Molecular Therapy - Methods and Clinical Development, 2020, 18, 803-810.	1.8	9
121	Characterization of Extracellular Vesicles Secreted in Lentiviral Producing HEK293SF Cell Cultures. Viruses, 2021, 13, 797.	1.5	9
122	A Four-Step Purification Process for Gag VLPs: From Culture Supernatant to High-Purity Lyophilized Particles. Vaccines, 2021, 9, 1154.	2.1	9
123	Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses, 2022, 14, 975.	1.5	9
124	Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza. PLoS ONE, 2017, 12, e0180314.	1.1	8
125	Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures. Vaccine, 2020, 38, 7949-7955.	1.7	8
126	A simple macroscopic model for the diffusion and adsorption kinetics of r-adenovirus. Biotechnology and Bioengineering, 2007, 98, 239-251.	1.7	7

#	Article	IF	Citations
127	Large-Scale Transient Transfection of Suspension Mammalian Cells for VLP Production. Methods in Molecular Biology, 2018, 1674, 117-127.	0.4	7
128	Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa. Vaccines, 2020, 8, 338.	2.1	7
129	Recent advances and current challenges in process intensification of cell cultureâ€based influenza virus vaccine manufacturing. Canadian Journal of Chemical Engineering, 2021, 99, 2525-2535.	0.9	7
130	Micro-quantitation of lipids in serum-free cell culture media: a critical aspect is the minimization of interference from medium components and chemical reagents. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 810, 119-127.	1.2	7
131	Increased Production of Active Human Î²2-Adrenergic/GÎ±s Fusion Receptor in Sf-9 Cells Using Nutrient Limiting Conditions. Protein Expression and Purification, 2001, 23, 66-74.	0.6	6
132	Rapid and reliable quantification of reovirus type 3 by high performance liquid chromatography during manufacturing of ReolysinÂ®. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 598-605.	1.4	6
133	Lentiviral Vector Production in Suspension Culture Using Serum-Free Medium for the Transduction of CAR-T Cells. Methods in Molecular Biology, 2020, 2086, 77-83.	0.4	6
134	Validation of a high-performance liquid chromatographic assay for the quantification of Reovirus particles type 3. Journal of Pharmaceutical and Biomedical Analysis, 2007, 45, 417-421.	1.4	5
135	Overview of recent advances in Vero cells genomic characterization and engineering for highâ€throughput vaccine manufacturing. Clinical and Translational Discovery, 2022, 2, .	0.2	5
136	Establishment of the upstream processing for renewable production of hydrogen using vermicomposting-tea and molasses as substrate. Waste Management, 2022, 139, 279-289.	3.7	4
137	Protein-free culture medium improvement: testing additives and their interactive effects in 96-well plates. Applied Microbiology and Biotechnology, 1993, 39, 577-584.	1.7	3
138	Production of Lentiviral Vectors Encoding Recombinant Factor VIII Expression in Serum-Free Suspension Cultures. Brazilian Archives of Biology and Technology, 2015, 58, 923-928.	0.5	3
139	292. Towards Large-Scale Manufacturing of Adeno-Associated Virus by Transient Transfection of HEK293 Suspension Cells in a Stirred Tank Bioreactor Using Serum-Free Medium. Molecular Therapy, 2016, 24, S117-S118.	3.7	3
140	Cell Transfection. , 2019, , 383-390.		3
141	Vaccine Technology VII: Beyond the â€œdecade of vaccinesâ€• Vaccine, 2019, 37, 6931-6932.	1.7	1
142	Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation. Vaccines, 2021, 9, 722.	2.1	1
143	Enhanced growth of sf-9 cells to a maximum density of 5.2 Ã— 107 cells per mL and production of Î²-galactosidase at high cell density by fed batch culture. , 2000, 68, 381.		1
144	Handling Massive Proportion of Missing Labels in Multivariate Long-Term Time Series Forecasting. Journal of Physics: Conference Series, 2021, 2090, 012170.	0.3	1

#	Article	IF	Citations
145	PRODUCTION AND PURIFICATION OF VIRAL VECTORS AND SAFETY CONSIDERATIONS RELATED TO THEIR USE. , 2019, , 565-587.		0